Arcosa, Inc. Announces First Quarter 2024 Results and Raises Full Year 2024 Guidance
First Quarter Revenues Up 9%, with Contribution From All Three Segments Adjusted EBITDA Growth of 7%, Normalizing for the $22 Million Land Sale Gain in 2023 Operating... Read more.
Reinsurance Group of America Reports First Quarter Results
First Quarter Results Net income available to RGA shareholders of $3.16 per diluted share Adjusted operating income* of $6.02 per diluted share Premium growth of... Read more.
Humana Inc. to Present at B of A Securities Health Care Conference 2024
LOUISVILLE, Ky.–(BUSINESS WIRE)–Humana Inc. (NYSE: HUM) announced today that Bruce D. Broussard, Chief Executive Officer, and Susan M. Diamond, Chief... Read more.
Five9 Reports First Quarter 2024 Results
13% Year-Over-Year Growth in Total Revenue 20% Year-Over-Year Growth in Subscription Revenue GAAP Operating Cash Flow of $32.4 Million SAN RAMON, Calif.–(BUSINESS... Read more.
Entravision Communications Corporation Reports First Quarter 2024 Results
Declares Quarterly Cash Dividend of $0.05 Per Share Payable on June 28, 2024 SANTA MONICA, Calif.–(BUSINESS WIRE)–Entravision Communications Corporation... Read more.
Stem Announces First Quarter 2024 Results
Substantial increase of +42% CARR-to-ARR conversion since January 2024 Introducing Next Generation Asset Performance Management Software Suite Reaffirming Full Year... Read more.
Coterra Energy Reports First-Quarter 2024 Results, Announces Quarterly Dividend, and Updates 2024 Outlook
HOUSTON–(BUSINESS WIRE)–Coterra Energy Inc. (NYSE: CTRA) (“Coterra” or the “Company”) today reported first-quarter 2024 financial and operating... Read more.
Upland Software Reports First Quarter 2024 Financial Results
AUSTIN, Texas–(BUSINESS WIRE)–Upland Software, Inc. (Nasdaq: UPLD), a leader in cloud-based tools for digital transformation, today announced financial... Read more.
4M Therapeutics Announces Formation of Clinical Advisory Board with Experts in Neuropsychiatry and Neurodegeneration
Appointees Andrew J. Cutler, M.D., Paul E. Keck, M.D., Jonathan Meyer, M.D., Andrew Nierenberg, M.D., and Gary Sachs, M.D. join clinical consultant, Maurizio Fava,... Read more.
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
Bexicaserin (LP352) Phase 1b/2a PACIFIC Study positive topline data in participants with Developmental and Epileptic Encephalopathies (DEEs) were reported in Q1... Read more.